Health Law Highlights

How Generative AI Is Shaping Drug Discovery

Summary of article from Healthcare Brew, by Mikaela Cohen:

Generative AI is revolutionizing drug discovery by significantly reducing the time and cost involved in developing new medicines, a process traditionally taking around a decade and $2.7 billion. Researchers are leveraging AI to identify new drug targets, design molecular structures, and expedite clinical trials, with AI-generated drugs moving from concept to first dose in as little as 1.5 years. However, ensuring high-quality, unbiased data is critical to the success of these AI systems. AI also holds promise in addressing patient recruitment challenges in clinical trials by simulating human genetic makeup and drug interactions. Despite these advancements, regulatory hurdles remain a significant challenge, with the need for health authorities to ensure AI’s efficacy and safety in drug development.